We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Atara Biotherapeutics (ATRA - Free Report) shares rallied 10% in the last trading session to close at $14.26. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.6% gain over the past four weeks.
The price rise can be attributed to growing investor optimism regarding Atara’s recent development related to its lead product candidate, tabelecleucel (tab-cel), a novel T-cell immunotherapy, which has been developed for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). The company’s resubmitted biologics license application for tab-cel is under priority review in the United States and a decision from the FDA is due on Jan. 10, 2026.
This drug developer is expected to post quarterly loss of $0.83 per share in its upcoming report, which represents a year-over-year change of +71.7%. Revenues are expected to be $1.29 million, down 96.8% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Atara Biotherapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ATRA going forward to see if this recent jump can turn into more strength down the road.
Atara Biotherapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Amicus Therapeutics (FOLD - Free Report) , another stock in the same industry, closed the last trading session 2.3% higher at $8.35. FOLD has returned 8.5% in the past month.
Amicus Therapeutics' consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.12. Compared to the company's year-ago EPS, this represents a change of +20%. Amicus Therapeutics currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock?
Atara Biotherapeutics (ATRA - Free Report) shares rallied 10% in the last trading session to close at $14.26. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.6% gain over the past four weeks.
The price rise can be attributed to growing investor optimism regarding Atara’s recent development related to its lead product candidate, tabelecleucel (tab-cel), a novel T-cell immunotherapy, which has been developed for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). The company’s resubmitted biologics license application for tab-cel is under priority review in the United States and a decision from the FDA is due on Jan. 10, 2026.
This drug developer is expected to post quarterly loss of $0.83 per share in its upcoming report, which represents a year-over-year change of +71.7%. Revenues are expected to be $1.29 million, down 96.8% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Atara Biotherapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ATRA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Atara Biotherapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Amicus Therapeutics (FOLD - Free Report) , another stock in the same industry, closed the last trading session 2.3% higher at $8.35. FOLD has returned 8.5% in the past month.
Amicus Therapeutics' consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.12. Compared to the company's year-ago EPS, this represents a change of +20%. Amicus Therapeutics currently boasts a Zacks Rank of #3 (Hold).